Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis
Research output: Contribution to journal › Journal article › Research › peer-review
Intracoronary (IC) administration of abciximab may increase local drug levels by several orders of magnitude compared to intravenous (IV) treatment and may improve clinical outcomes in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI). In the absence of results from large multicenter, randomized trials, we performed a systematic review and meta-analysis of available studies comparing IC to IV abciximab in these patients.
Original language | English |
---|---|
Journal | Journal of Invasive Cardiology |
Volume | 22 |
Issue number | 6 |
Pages (from-to) | 278-82 |
Number of pages | 5 |
ISSN | 1042-3931 |
Publication status | Published - 1 Jun 2010 |
ID: 34077456